Infantile Spasms Therapeutics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2023-28
                     Global Infantile Spasms 
Therapeutics Market 
Research and Forecast 
Report 2023-2028
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  t he  la tes t  repo r t  by  IM ARC Group,  t i t l ed  " In fan t i le  Spasms 
Therapeut ics  Market :  G l obal  Indust ry  T rends,  Share ,  S ize ,  Growth ,  
Oppor tun i ty  and  Forecast  2023-2028 ,"  t he  g loba l  i n fan t i l e  spasms the rapeut i cs  
marke t  s i ze  reached  US$  3 . 5  B i l l i on  in  2022 .
Report I n fan t i l e  spasms,  a lso  known as  Wes t  synd rome,  re fe rs  t o  a  ra re  and seve re  fo rm o f  ep i l epsy  t ha t  t yp ica l l y  a f fec t s  in fan t s  be tween  the  ages  o f  3  and  12  mon t hs .  
They  are  cha rac te r i zed  by  b r i e f  symmet r i c  musc le  con t rac t ions  tha t  can  cause the  
Highlight and body  or  l imbs  t o  je r k  o r  f l ex .  
They  can  be  d iagnosed by  phys ica l  examina t ion ,  neu ro log ica l  examina t i on ,  
Description magnet i c  resonance imag ing  (MRI )  o f  t he  b ra in ,  and  b lood  and ur ine  examina t ions .  They  invo lve  a  comb ina t ion  o f  med ica t ion  and  t he rap ies ,  such  as  
s t e ro ids ,  hormone  t he rapy  w i th  co r t i co t rop in  in jec t ion  ge l  and  g lucoco r t i co ids ,  
and  an t i se izu re  med ica t i ons .
Request  fo r  a  PDF sample  o f  th is  repor t :  
ht tps : / / www. imarcgroup .com/ in f an t i l e -spasms- therapeut i cs -m arke t / reques t samp le
Report Description
Global  In fant i le  Spasms Therapeut ics  Market  Trends :
The inc reas ing  inc idences  o f  i n fan t i l e  spasms among in fan ts  rep resen t  one  o f  the  ma jo r  f ac to rs  d r iv ing  the  
demand fo r  i n fan t i l e  spasms the rapeu t ics  a round  the  wo r ld .  Moreover ,  the  r i s ing  awareness  abou t  t he  ea r l y  s igns  
and  symp toms o f  i n fan t i le  spasms and  imp roved  d iagnos t ics  capab i l i t ies  i s  f avor ing  the  g rowth  o f  the  marke t .  
In  add i t ion ,  gove rn ing  agenc ies  o f  seve ra l  coun t r ies  a re  o f fe r ing  f inanc ia l  ass is tance  fo r  in fan t i le  spasms 
t rea tment  to  min im ize  hea l thca re  expenses .  Apar t  f rom th i s ,  t hey  a re  f i nanc ing  resea rch  and  deve lopmen t  (R&D)  
p ro jec ts  to  i den t i f y  and  deve lop  nove l  t he rapeu t ic  agen ts .  Th is ,  coup led  w i th  the  inc reas ing  number  o f  c l in ica l  
t r ia l s  by  pharmaceu t ica l  compan ies ,  i s  augmen t ing  the  g rowth  o f  the  marke t .
Look ing  forward ,  the  market  va lue  is  pro jected to  reach US$ 4 .5  B i l l ion  by  2028 ,  expanding a t  a  CAGR of  
4 .2% dur ing  2023-2028 .
V iew Repor t  TOC,  F igures  and  Tables :  h t tps: / /www. imarcgroup.com/ infant i le -spasms- therapeut ics-market
Therapeutic Class Insights:
• Anticonvulsants
• Cort icosteroids
• Others
 
Drug Type Insights:
• Vigabatr in
• Adrenocort icotropic  Hormone
Report • Others (Phase I I I )
Segmentation
Dosage Insights:
• Sol id
• Liquid
Route of Administration Insights:
• Oral
• Parenteral
• Others
Distribution Channel Insights:
• Hospital  Pharmacy
• Retai l  Pharmacy
• Onl ine Pharmacy
End User Insights:
• Hospitals
Report 
• Clinics
Segmentation • Others
Regional Insights:
• North America
• Asia-Pacifi c
• Europe
• Latin America
• Middle East and Afr ica
• H. Lundbeck A/S
• Mall inckrodt plc
• ORPHELIA Pharma
Competitive 
• Teva Pharmaceuticals USA Inc. (Teva 
Landscape Pharmaceutical Industr ies Ltd.)
with Key 
Players
How big is the global infantile spasms therapeutics 
market?
What is the expected growth rate of the global infantile 
spasms therapeutics market during 2023-2028?
Key What are the key factors driving the global infantile 
spasms therapeutics market?
Questions 
Answered in What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
the Report
What is the breakup of the global infantile spasms 
therapeutics market based on the therapeutic class?
What is the breakup of the global infantile spasms 
therapeutics market based on the drug type?
What is the breakup of the global infantile spasms 
therapeutics market based on the dosage?
What is the breakup of the global infantile spasms 
therapeutics market based on route of administration?
What is the breakup of the global infantile spasms 
therapeutics market based on the distribution channel?
Key What is the breakup of the global infantile spasms 
therapeutics market based on the end user?
Questions 
What are the key regions in the global infantile spasms 
Answered in therapeutics market?
the Report
Who are the key players/companies in the global 
infantile spasms therapeutics market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  I n f a n t i l e  S p a s m s  T h e r a p e u t i c s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  T h e r a p e u t i c  C l a s s
    6 . 1     A n t i c o n v u l s a n t s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     C o r t i c o s t e r o i d s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     O t h e r s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
7     M a r k e t  B r e a k u p  b y  D r u g  T y p e
       
    7 . 1     V i g a b a t r i n
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     A d r e n o c o r t i c o t r o p i c  H o r m o n e
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     O t h e r s  ( P h a s e  I I I )
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8     M a r k e t  B r e a k u p  b y  D o s a g e  
    8 . 1     S o l i d
Table of         8 . 1 . 1  M a r k e t  T r e n d s        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     L i q u i d
        8 . 2 . 1  M a r k e t  T r e n d s
Contents         8 . 2 . 2  M a r k e t  F o r e c a s t9     M a r k e t  B r e a k u p  b y  R o u t e  o f  A d m i n i s t r a t i o n
    9 . 1     O r a l
        9 . 1 . 1  M a r k e t  T r e n d s
        9 . 1 . 2  M a r k e t  F o r e c a s t
    9 . 2     P a r e n t e r a l
        9 . 2 . 1  M a r k e t  T r e n d s
        9 . 2 . 2  M a r k e t  F o r e c a s t
    9 . 3     O t h e r s
        9 . 3 . 1  M a r k e t  T r e n d s
        9 . 3 . 2  M a r k e t  F o r e c a s t
10      Market  B reakup  by  D is t r ibut ion  C hanne l
      1 0 . 1      H o s p i t a l  Ph a rm a cy
            1 0 . 1 . 1  M a r ke t  Tren d s
            1 0 . 1 . 2  M a r ke t  Fo re ca s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / in f a n t i l e - s pa s m s - t h e r a p e u t i c s - m a r
ke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]